Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007). ClinicalTrials.gov record last updated 2026-09-25: recruiting. Enrollment is planned at 614 participants. Primary completion is estimated at 2028-01-25. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures. Registered primary measures: Overall Survival (OS).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Merck & Co. (MSD), Small-cell lung cancer, Pembrolizumab.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/